Celgene Corporation today announced that findings from ongoing clinical trials of OTEZLA , the Company’s oral, selective inhibitor of phosphodiesterase 4 , conducted in patients with moderate or moderate to severe plaque psoriasis, and in adult patients with active psoriatic arthritis, will be presented at the 75th Annual Meeting of the American Academy of Dermatology in Orlando, Florida. Ten abstracts will be presented at the meeting.
Category: Celgene
Top Biotech Stocks to Buy in 2017
Many individual biotech stocks have performed far worse. One bright side to all of that selling is that a handful of high-quality biotech stocks are currently trading for attractive prices.
Is Celgene Simply the Best Biotech Stock on the Planet?
Celgene traditionally kicks off the conference and did so again this year. Alles briefly described what the biotech has done recently, where it’s headed, and how it plans to get there.
Therapy Focus – Immunotherapy Closes In On Triple-Negative Tumors
Celgene admitted as much last week by saying it would not push a promising Abraxane-containing chemotherapy regimen into pivotal trials in this Several studies are already under way, most notably a large first-line phase III trial of Abraxane plus Roche’s anti-PD-L1 antibody Tecentriq. Early data are encouraging, and hopes are high that meaningful survival benefits will emerge in the next couple of years.